Once-daily Vyvanse^® CII (lisdexamfetamine dimseylate) capsules, approved for children ages 6 to 12, adolescents ages 13 to 17, and adults with ADHD.

Indication

Vyvanse is indicated for the treatment of ADHD in patients ages 6 and above as part of a total treatment plan that may include other measures (psychological, educational, social). Efficacy was established in short-term controlled studies in children aged 6 to 17 and adults. Vyvanse is also approved as a maintenance treatment for adults with ADHD based on one randomized withdrawal study. Extended use of Vyvanse should be periodically reevaluated to determine its long-term usefulness for the individual patient.

Important Safety Information

• Contraindications: Known hypersensitivity to amphetamines or other ingredients in Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports. Using Vyvanse with monoamine oxidase inhibitors (MAOIs) can result in hypertensive crisis. Stop MAOIs at least 14 days prior to Vyvanse use.
• Sudden death, stroke and myocardial infarction have been reported with stimulants at usual doses for the treatment of ADHD. Stimulants generally should not be used in patients with known structural cardiac abnormalities or other serious heart problems. Adults have a greater likelihood than children of having such cardiac disease. Patients being considered for stimulant treatment should have a careful history (including family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease. Further evaluation should be conducted if needed (eg, electrocardiogram and echocardiogram). Patients who develop symptoms suggestive of cardiac disease (eg, exertional chest pain, unexplained syncope) during stimulant treatment should undergo a prompt evaluation.
• Use with caution in patients whose underlying medical condition might be compromised by increases in blood pressure or heart rate. Stimulants cause modest increases in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm) and patients may have larger increases. Monitor all patients for larger changes.
• Use of stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis. Clinical evaluation for bipolar disorder is recommended prior to stimulant use. Monitor for aggressive behavior.
• Monitor growth in children during treatment with Vyvanse. Children who are not growing (gaining height or weight) as expected may need to have their treatment interrupted.
• Stimulants may lower the convulsive threshold. Discontinue if seizures develop.
• Visual disturbances and exacerbation of tics and Tourette's syndrome have been reported with stimulant treatment.
• The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in clinical trials were:
  • Children ages 6 to 12: decreased appetite, insomnia, upper abdominal pain, irritability, decreased weight, vomiting, nausea, dizziness and dry mouth;
  • Adolescents ages 13 to 17: decreased appetite, insomnia, and decreased weight;
  • Adults: decreased appetite, insomnia, dry mouth, nausea, diarrhea, anxiety and anorexia.

Please click here for Full Prescribing Information, including Boxed WARNING regarding Potential for Misuse, Abuse, Addiction, and Diversion.

Shire US Inc. will not sell or provide your e-mail information to other parties without your permission. This information will not be used for any purpose other than to notify you of future programs, and provide you with more efficient customer service response. Please view our full Privacy Policy.

©2012 Shire US Inc., Wayne, PA 19087. 1-800-828-2088. All rights reserved. This site is solely intended for US residents and is governed solely by US laws and government regulations. Please see our online privacy policy for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

Vyvanse^® is a registered trademark of Shire LLC.

• Contact Us
• Site Map
• Privacy Policy
• Unsubscribe
• Full Prescribing Information
• Medication Guide

VYV-03603  04/12